AKT1 is altered in 1.32% of small cell lung carcinoma patients [2].

AKT1 is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

AKT2 is altered in 4.0% of small cell lung carcinoma patients [2].

AKT2 is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

AKT3 is altered in 1.8% of small cell lung carcinoma patients [2].

AKT3 is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT3 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

ARID1A is altered in 6.55% of small cell lung carcinoma patients [2].

ARID1A is an inclusion eligibility criterion in 3 clinical trials for small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ARID1A status and small cell lung carcinoma as inclusion criteria, 3 are phase 1/phase 2 (3 open) [3].

ATM is altered in 3.75% of small cell lung carcinoma patients [2].

ATM is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain ATM status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

ATR is altered in 6.78% of small cell lung carcinoma patients [2].

ATR is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain ATR status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

ATRX is altered in 10.79% of small cell lung carcinoma patients [2].

ATRX is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATRX status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BAP1 is altered in 3.98% of small cell lung carcinoma patients [2].

BAP1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BARD1 is altered in 1.62% of small cell lung carcinoma patients [2].

BARD1 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain BARD1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

BCL2 is altered in 1.37% of small cell lung carcinoma patients [2].

BCL2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BCL6 is altered in 3.85% of small cell lung carcinoma patients [2].

BCL6 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BLM is altered in 1.79% of small cell lung carcinoma patients [2].

BLM is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

BRAF is altered in 2.62% of small cell lung carcinoma patients [2].

BRAF is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

BRCA1 is altered in 1.99% of small cell lung carcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 6 clinical trials for small cell lung carcinoma, of which 4 are open and 2 are closed. Of the trials that contain BRCA1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (1 open) [3].

BRCA2 is altered in 4.69% of small cell lung carcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 6 clinical trials for small cell lung carcinoma, of which 4 are open and 2 are closed. Of the trials that contain BRCA2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (1 open) [3].

BRIP1 is altered in 2.49% of small cell lung carcinoma patients [2].

BRIP1 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain BRIP1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

C11orf30 is altered in 0.44% of small cell lung carcinoma patients [2].

C11orf30 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains C11orf30 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CDK12 is altered in 1.61% of small cell lung carcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 4 clinical trials for small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CDK12 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (3 open) [3].

CDKN2A is altered in 4.62% of small cell lung carcinoma patients [2].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CHEK1 is altered in 1.86% of small cell lung carcinoma patients [2].

CHEK1 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain CHEK1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

CHEK2 is altered in 1.8% of small cell lung carcinoma patients [2].

CHEK2 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain CHEK2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

CRKL is altered in 1.12% of small cell lung carcinoma patients [2].

CRKL is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

EGFR is altered in 9.38% of small cell lung carcinoma patients [2].

EGFR is an inclusion eligibility criterion in 4 clinical trials for small cell lung carcinoma, of which 4 are open and 0 are closed. Of the trials that contain EGFR status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

ERBB2 is altered in 2.64% of small cell lung carcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

ERCC2 is altered in 2.73% of small cell lung carcinoma patients [2].

ERCC2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC3 is altered in 1.16% of small cell lung carcinoma patients [2].

ERCC3 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC3 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC4 is altered in 2.3% of small cell lung carcinoma patients [2].

ERCC4 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC4 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC5 is altered in 4.21% of small cell lung carcinoma patients [2].

ERCC5 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC5 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC6 is altered in 0.39% of small cell lung carcinoma patients [2].

ERCC6 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC6 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCA is altered in 3.6% of small cell lung carcinoma patients [2].

FANCA is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCA status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FANCB is altered in 2.27% of small cell lung carcinoma patients [2].

FANCB is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCB status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FANCC is altered in 0.68% of small cell lung carcinoma patients [2].

FANCC is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCC status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FANCD2 is altered in 2.05% of small cell lung carcinoma patients [2].

FANCD2 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCD2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FANCE is altered in 1.41% of small cell lung carcinoma patients [2].

FANCE is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCE status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FANCF is altered in 1.41% of small cell lung carcinoma patients [2].

FANCF is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCF status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FANCG is altered in 0.74% of small cell lung carcinoma patients [2].

FANCG is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCG status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FANCI is altered in 2.08% of small cell lung carcinoma patients [2].

FANCI is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCI status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FANCL is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCL status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FANCM is altered in 2.27% of small cell lung carcinoma patients [2].

FANCM is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCM status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FGFR1 is altered in 8.3% of small cell lung carcinoma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

FGFR2 is altered in 1.15% of small cell lung carcinoma patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

FGFR3 is altered in 3.58% of small cell lung carcinoma patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

HDAC1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HDAC2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HRAS is altered in 1.9% of small cell lung carcinoma patients [2].

HRAS is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HRAS status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

KIT is altered in 4.92% of small cell lung carcinoma patients [2].

KIT is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KRAS is altered in 4.1% of small cell lung carcinoma patients [2].

KRAS is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain MCPH1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

MDM2 is altered in 1.11% of small cell lung carcinoma patients [2].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MDM4 is altered in 1.11% of small cell lung carcinoma patients [2].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLH1 is altered in 1.76% of small cell lung carcinoma patients [2].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLH3 is altered in 4.26% of small cell lung carcinoma patients [2].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MRE11A is altered in 2.45% of small cell lung carcinoma patients [2].

MRE11A is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain MRE11A status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

MSH2 is altered in 2.2% of small cell lung carcinoma patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MSH3 is altered in 1.4% of small cell lung carcinoma patients [2].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MSH6 is altered in 1.53% of small cell lung carcinoma patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MTOR is altered in 4.32% of small cell lung carcinoma patients [2].

MTOR is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MUTYH is altered in 1.35% of small cell lung carcinoma patients [2].

MUTYH is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MUTYH status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYC is altered in 5.49% of small cell lung carcinoma patients [2].

MYC is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MYC status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

MYCL is altered in 5.72% of small cell lung carcinoma patients [2].

MYCL is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYCL status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

MYCN is altered in 2.18% of small cell lung carcinoma patients [2].

MYCN is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

NBN is altered in 3.23% of small cell lung carcinoma patients [2].

NBN is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain NBN status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

NPM1 is altered in 1.27% of small cell lung carcinoma patients [2].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRAS is altered in 1.35% of small cell lung carcinoma patients [2].

NRAS is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PALB2 is altered in 2.91% of small cell lung carcinoma patients [2].

PALB2 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain PALB2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

PARP1 is altered in 2.91% of small cell lung carcinoma patients [2].

PARP1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PARP2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PDGFRA is altered in 5.52% of small cell lung carcinoma patients [2].

PDGFRA is an inclusion eligibility criterion in 3 clinical trials for small cell lung carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PDGFRA status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (1 open) [3].

PDGFRB is altered in 3.6% of small cell lung carcinoma patients [2].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PDGFRB status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

PIK3CA is altered in 9.38% of small cell lung carcinoma patients [2].

PIK3CA is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CA status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PIK3CG is altered in 7.12% of small cell lung carcinoma patients [2].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R1 is altered in 2.37% of small cell lung carcinoma patients [2].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R2 is altered in 2.22% of small cell lung carcinoma patients [2].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PMS1 is altered in 3.02% of small cell lung carcinoma patients [2].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PMS2 is altered in 1.13% of small cell lung carcinoma patients [2].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

POLE is altered in 4.32% of small cell lung carcinoma patients [2].

POLE is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PPP2R1A is altered in 0.26% of small cell lung carcinoma patients [2].

PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R1A status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PPP2R2A is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PPP2R2A status and small cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

PTEN is altered in 10.72% of small cell lung carcinoma patients [2].

PTEN is an inclusion eligibility criterion in 7 clinical trials for small cell lung carcinoma, of which 5 are open and 2 are closed. Of the trials that contain PTEN status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 4 are phase 1/phase 2 (4 open), and 2 are phase 2 (1 open) [3].

RAD50 is altered in 1.56% of small cell lung carcinoma patients [2].

RAD50 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain RAD50 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

RAD51 is altered in 1.14% of small cell lung carcinoma patients [2].

RAD51 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain RAD51 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

RAD51B is altered in 1.25% of small cell lung carcinoma patients [2].

RAD51B is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain RAD51B status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

RAD51C is altered in 0.28% of small cell lung carcinoma patients [2].

RAD51C is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain RAD51C status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

RAD51D is altered in 0.85% of small cell lung carcinoma patients [2].

RAD51D is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain RAD51D status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

RAD52 is altered in 1.43% of small cell lung carcinoma patients [2].

RAD52 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD52 status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

RAD54L is altered in 1.63% of small cell lung carcinoma patients [2].

RAD54L is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain RAD54L status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

RECQL4 is altered in 5.25% of small cell lung carcinoma patients [2].

RECQL4 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RECQL4 status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

RICTOR is altered in 7.61% of small cell lung carcinoma patients [2].

RICTOR is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RICTOR status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

RPA1 is altered in 2.22% of small cell lung carcinoma patients [2].

RPA1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RPA1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

RPTOR is altered in 3.75% of small cell lung carcinoma patients [2].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SLX4 is altered in 5.43% of small cell lung carcinoma patients [2].

SLX4 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain SLX4 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

SMARCB1 is altered in 0.38% of small cell lung carcinoma patients [2].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

STAG2 is altered in 4.93% of small cell lung carcinoma patients [2].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

STK11 is altered in 2.08% of small cell lung carcinoma patients [2].

STK11 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TP53 is altered in 82.84% of small cell lung carcinoma patients [2].

TP53 is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 0 are open and 2 are closed. Of the trials that contain TP53 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [3].

TSC1 is altered in 1.78% of small cell lung carcinoma patients [2].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC2 is altered in 4.51% of small cell lung carcinoma patients [2].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

VEGFA is altered in 1.76% of small cell lung carcinoma patients [2].

VEGFA is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains VEGFA status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

VEGFB is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains VEGFB status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

WRN is altered in 1.54% of small cell lung carcinoma patients [2].

WRN is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains WRN status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

XRCC1 is altered in 2.27% of small cell lung carcinoma patients [2].

XRCC1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].